Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Transgenic mice for in vivo epigenome editing with CRISPR-based systems

Journal article

Gemberling MP. et al, (2021), Nature Methods

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.

Journal article

Kantor A. and Haga SB., (2021), J Pers Med, 11

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?

Journal article

Han RC. et al, (2021), Expert Opinion on Orphan Drugs, 9, 13 - 24

CRISPR genome engineering for retinal diseases

Chapter

Kantor A. et al, (2021), Progress in Molecular Biology and Translational Science

Genome-Editing Strategies for Treating Human Retinal Degenerations

Journal article

Quinn J. et al, (2020), Human Gene Therapy

CRISPR-Cas9 DNA Base-Editing and Prime-Editing.

Journal article

Kantor A. et al, (2020), Int J Mol Sci, 21

Comparison of Cas9 Orthologues for Gene Suppression Activity

Conference paper

Kantor A. et al, (2020), MOLECULAR THERAPY, 28, 103 - 104

Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing

Journal article

Haga SB. and Kantor A., (2018), Health Affairs, 37, 717 - 723